Determinants of Brain Natriuretic Peptide in Diabetes

糖尿病脑钠肽的决定因素

• 批准号: 7585555
• 负责人: Alain Gerald Bertoni
• 金额: $ 28.65万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-01-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7585555
• 关键词: Acute; Address; Adult; Ancillary Study; Blood; Blood Pressure; Blood Tests; Blood specimen; Body Weight decreased; Body mass index; Brain natriuretic peptide; Cardiac; Cardiac Myocytes; Cardiovascular Diseases; Cardiovascular system; Cessation of life; Characteristics; Cleaved cell; Clinical; Comorbidity; Complications of Diabetes Mellitus; Congenital Heart Defects; Coronary Arteriosclerosis; Cross-Sectional Studies; Data; Diabetes Mellitus; Diagnosis; Disease; Echocardiography; Education; Elderly; Electrocardiogram; Energy Intake; Enrollment; Event; Exploratory/Developmental Grant; Freezing; Future; Gender; Glycosylated hemoglobin A; Goals; Grant; Health; Heart Diseases; Heart failure; Hypertension; Incidence; Injury; Lead; Life Style; Literature; Long-Term Effects; Magnetic Resonance Imaging; Measurement; Measures; Morbidity - disease rate; Myocardial Infarction; Myocardial Ischemia; NT-proBNP; National Health and Nutrition Examination Survey; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Natriuretic Peptides; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Overweight; Participant; Patients; Persons; Pharmaceutical Preparations; Physical activity; Population; Prevention; Public Health; Randomized Controlled Clinical Trials; Records; Research; Resources; Risk; Risk Factors; Sample Size; Sampling; Stratification; Stretching; Stroke; Subgroup; Testing; Time; United States; United States National Institutes of Health; Upper arm; Ventricular; Weight; abstracting; adjudicate; cohort; cost; diabetes education; diabetic; diabetic cardiomyopathy; diabetic patient; glycemic control; high risk; interest; intervention effect; lifestyle intervention; mortality; obesity risk; prevent; prospective; response; secondary outcome; therapy design; trend; weight loss intervention

DESCRIPTION (provided by applicant): Abstract Type 2 diabetes mellitus (T2DM) is a strong risk factor for heart failure (HF), and is increasingly prevalent in the US. Epidemiologic evidence suggests increased blood pressure, higher hemoglobin A1c and increased obesity are risk factors for HF among diabetics. Currently there is not a simple, clinically useful way to risk- stratify diabetic patients with respect to future HF risk. This has led to interest in utilizing a blood test measuring NT-proBNP as part of risk stratification in persons with diabetes. Cardiac myocytes release proBNP, which is cleaved into the active BNP and inactive NT-proBNP, which is more stable in blood. The two are highly correlated and are utilized in diagnosing acute HF. NT-proBNP has been shown to be predictive of future HF, other cardiovascular events, and mortality. However small studies have suggested that increased body mass index (BMI) and A1c is associated with lower, rather than higher BNP/NT-pro BNP levels, in diabetics. These associations are counterintuitive, given the suggested relationship between HbA1c or BMI and HF. Furthermore, there is little data regarding change in NT-proBNP over time in diabetics without overt heart failure. Understanding the true relationship between risk factors for HF and NT-proBNP in T2DM is required before it could be useful to target HF prevention. Thus we propose an ancillary study to Look AHEAD (Action for Health in Diabetes) a multicenter, randomized trial which enrolled 5,145 overweight and obese adults with T2DM during 2001-04, to determine the long-term effects of an intensive lifestyle intervention designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity versus a control condition, diabetes support and education (DSE), on the combined incidence of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. At one year, the effect of the intervention on weight was -8.3%, compared to -0.4% in the DSE group. This study proposes to test for NT- proBNP in 1500 Look AHEAD participants free of cardiovascular disease (750 in each arm) in stored frozen blood samples from baseline and one year. This study will lead to a better understanding of the correlates of NT-proBNP in overweight diabetic adults, and determine if a lifestyle intervention reduces NT-proBNP. The research proposed may lead to efforts to better identify diabetic adults at high risk for heart failure, and target prevention efforts. This is important, as heart failure is a common, deadly, and expensive illness in the U.S.PUBLIC HEALTH RELEVANCE It is known that blood levels of NT-proBNP can predict who will develop heart disease, including heart failure, but among diabetic persons, to determinants of NT-proBNP are not clear. This project aims to better understand NT-proBNP levels, and to test whether a weight loss intervention reduces the amount of NT- proBNP in the blood of diabetics. This may help better prevent heart failure in diabetics, which is important because heart failure is a common and deadly complication of diabetes.

描述（由申请人提供）：摘要2型糖尿病（T2 DM）是心力衰竭（HF）的一个强风险因素，在美国日益流行。流行病学证据表明，血压升高、血红蛋白A1 c升高和肥胖增加是糖尿病患者发生HF的危险因素。目前还没有一种简单的、临床上有用的方法来对糖尿病患者未来的HF风险进行风险分层。这引起了人们对利用测量NT-proBNP的血液测试作为糖尿病患者风险分层的一部分的兴趣。心肌细胞释放proBNP，proBNP被切割成活性BNP和在血液中更稳定的非活性NT-proBNP。两者高度相关，用于诊断急性HF。已证明NT-proBNP可预测未来HF、其他心血管事件和死亡率。然而，小型研究表明，在糖尿病患者中，体重指数（BMI）和A1 c的增加与BNP/NT-pro BNP水平的降低而不是升高相关。考虑到HbA 1c或BMI与HF之间的关系，这些关联是违反直觉的。此外，几乎没有关于无明显心力衰竭的糖尿病患者NT-proBNP随时间变化的数据。了解T2 DM患者中HF风险因素与NT-proBNP之间的真实关系，才能有助于针对HF的预防。因此，我们建议进行一项辅助研究，（糖尿病健康行动）一项多中心、随机试验，在2001-04年期间入组了5，145例超重和肥胖的T2 DM成人，以确定强化生活方式干预的长期效果，该干预旨在通过减少热量摄入和增加体力活动来实现并维持体重减轻，与对照组相比，糖尿病支持和教育（DSE）对心血管死亡、非致死性心肌梗死和非致死性卒中的联合发生率的影响。一年后，干预对体重的影响为-8.3%，而DSE组为-0.4%。本研究拟在1500名无心血管疾病的Look AHEAD参与者（每组750名）中检测基线和一年后储存的冷冻血液样本中的NT- proBNP。这项研究将有助于更好地了解超重糖尿病成人中NT-proBNP的相关性，并确定生活方式干预是否会降低NT-proBNP。这项研究可能会导致更好地识别心力衰竭高风险的糖尿病成年人，并有针对性地预防。这一点很重要，因为心力衰竭在美国是一种常见的、致命的、昂贵的疾病。众所周知，NT-proBNP的血液水平可以预测谁会患上心脏病，包括心力衰竭，但在糖尿病患者中，NT-proBNP的决定因素尚不清楚。该项目旨在更好地了解NT-proBNP水平，并测试减肥干预是否会减少糖尿病患者血液中NT-proBNP的含量。这可能有助于更好地预防糖尿病患者的心力衰竭，这很重要，因为心力衰竭是糖尿病常见且致命的并发症。